GLPwatch
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
NCT06716424 · Active, not recruiting
Last updated 2026-05-28This trial tests the safety of a combination diabetes medication called iGlarLixi in adults with type 2 diabetes.
Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design open-label (no blinding) study
Participants 105 people
Who can join Ages 18+ · all sexes
Timeline Started 2025-01 · est. completion 2026-06
Where 10 sites · India
What this study is testing ClinicalTrials.gov NCT06716424 ↗
Description as written by the study sponsor.
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
Treatments tested
- iGlarLixi (insulin glargine/lixisenatide) also known as Soliqua®, Solostar® Drug
iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
| Main thing measured | Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) |
|---|---|
| Sponsor | Sanofi |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06716424 ↗